These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30773203)

  • 1. Development of Ultrasound-Triggered and Magnetic-Targeted Nanobubble System for Dual-Drug Delivery.
    Hamarat Şanlıer Ş; Ak G; Yılmaz H; Ünal A; Bozkaya ÜF; Tanıyan G; Yıldırım Y; Yıldız Türkyılmaz G
    J Pharm Sci; 2019 Mar; 108(3):1272-1283. PubMed ID: 30773203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of pemetrexed by magnetic nanoparticles: design, characterization,
    Ak G; Aksu D; Çapkın E; Sarı Ö; Kımız Geboloğlu I; Şanlıer ŞH
    Prep Biochem Biotechnol; 2020; 50(3):215-225. PubMed ID: 31750758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
    He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
    Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV; Felip E; Besse B; von Pawel J; Mellemgaard A; Reck M; Bosquee L; Chouaid C; Lianes-Barragán P; Paul EM; Ruiz-Soto R; Sigal E; Ottesen LH; Lechevalier T
    J Thorac Oncol; 2013 Dec; 8(12):1529-37. PubMed ID: 24389434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.
    Ishikura N; Yanagisawa M; Noguchi-Sasaki M; Iwai T; Yorozu K; Kurasawa M; Sugimoto M; Yamamoto K
    Anticancer Res; 2017 Feb; 37(2):623-629. PubMed ID: 28179309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
    Kong L; Cai FY; Yao XM; Jing M; Fu M; Liu JJ; He SY; Zhang L; Liu XZ; Ju RJ; Li XT
    Cancer Sci; 2020 Feb; 111(2):621-636. PubMed ID: 31777993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
    Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
    Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor and antimetastatic effects of pemetrexed-loaded targeted nanoparticles in B
    Lu N; Li R; Liu Q; Hu B; Xu X; Ji C; Han X; Wang P; Liu B
    Drug Deliv; 2016 Sep; 23(7):2566-2574. PubMed ID: 26000825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
    Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
    Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Cellular Uptake and Gene Silencing Activity of Survivin-siRNA via Ultrasound-Mediated Nanobubbles in Lung Cancer Cells.
    Akbaba H; Erel-Akbaba G; Kotmakçı M; Başpınar Y
    Pharm Res; 2020 Aug; 37(8):165. PubMed ID: 32761250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumor drug accumulation and limiting bioavailability and toxicity in normal tissues.
    Ingram N; McVeigh LE; Abou-Saleh RH; Maynard J; Peyman SA; McLaughlan JR; Fairclough M; Marston G; Valleley EMA; Jimenez-Macias JL; Charalambous A; Townley W; Haddrick M; Wierzbicki A; Wright A; Volpato M; Simpson PB; Treanor DE; Thomson NH; Loadman PM; Bushby RJ; Johnson BRG; Jones PF; Evans JA; Freear S; Markham AF; Evans SD; Coletta PL
    Theranostics; 2020; 10(24):10973-10992. PubMed ID: 33042265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer specific and reduction-responsive chimaeric polymersomes for highly efficient loading of pemetrexed and targeted suppression of lung tumor in vivo.
    Yang W; Yang L; Xia Y; Cheng L; Zhang J; Meng F; Yuan J; Zhong Z
    Acta Biomater; 2018 Apr; 70():177-185. PubMed ID: 29410335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
    Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
    Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effectiveness of a combined therapy with a new cucurbitacin B derivative and paclitaxel on a human lung cancer xenograft model.
    Marostica LL; de Barros ALB; Oliveira J; Salgado BS; Cassali GD; Leite EA; Cardoso VN; Lang KL; Caro MSB; Durán FJ; Schenkel EP; de Oliveira MC; Simões CMO
    Toxicol Appl Pharmacol; 2017 Aug; 329():272-281. PubMed ID: 28610991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential HIFU heating and nanobubble encapsulation provide efficient drug penetration from stealth and temperature sensitive liposomes in colon cancer.
    VanOsdol J; Ektate K; Ramasamy S; Maples D; Collins W; Malayer J; Ranjan A
    J Control Release; 2017 Feb; 247():55-63. PubMed ID: 28042085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preparation of magnetic solid liposome nanoparticles of paclitaxel].
    Xin SC; Wu XR; Zhou LZ
    Yao Xue Xue Bao; 2006 Oct; 41(10):933-8. PubMed ID: 17184109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic and therapeutic study of novel anti-tumor function of natural compound imperialine for treating non-small cell lung cancer.
    Lin Q; Qu M; Patra HK; He S; Wang L; Hu X; Xiao L; Fu Y; Gong T; He Q; Zhang L; Sun X; Zhang Z
    J Ethnopharmacol; 2020 Jan; 247():112283. PubMed ID: 31605736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer.
    Xiong Y; Zhao Y; Miao L; Lin CM; Huang L
    J Control Release; 2016 Dec; 244(Pt A):63-73. PubMed ID: 27840166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid crystalline assembly for potential combinatorial chemo-herbal drug delivery to lung cancer cells.
    Abdelaziz HM; Elzoghby AO; Helmy MW; Samaha MW; Fang JY; Freag MS
    Int J Nanomedicine; 2019; 14():499-517. PubMed ID: 30666110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.